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INTRODUCTION
Age-related macular degeneration (AMD) is an eye 
disease that affects the central part of the retina called 
the macula and in its late form, results in loss of cen-
tral vision. Late AMD is the most common cause of 
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ABSTRACT
Purpose: At the macula, the carotenoids meso-zeaxanthin (MZ), lutein (L), and zeaxanthin (Z) are 
collectively referred to as macular pigment (MP). This study was designed to measure serum and 
macular responses to a macular carotenoid formulation.
Materials and Methods: Ten subjects were recruited into this study (five normal and five with early 
age-related macular degeneration [AMD]). Subjects were instructed to consume a formulation 
containing 7.3 mg of MZ, 3.7 mg of L, and 0.8 mg of Z everyday over an eight-week period. The 
spatial profile of MP optical density (i.e., MPOD at 0.25°, 0.5°, 1°, and 1.75°) was measured using 
customized heterochromatic flicker photometry, and a blood sample was collected at each study 
visit in order to analyze serum concentrations of MZ, L, and Z.
Results: There was a significant increase in serum concentrations of MZ and L after two weeks of 
supplementation (p < 0.05). Baseline serum carotenoid analysis detected a small peak eluting at 
the same time as MZ in all subjects, with a mean ± SD of 0.02 ± 0.01 μmol/L. We report significant 
increases in MPOD at 0.25°, 0.5°, 1°, and average MPOD across the spatial profile after just two 
weeks of supplementation (p < 0.05, for all). Four subjects (one normal and three AMD) who had an 
atypical MPOD spatial profile at baseline had the more typical MPOD spatial profile (i.e., highest 
MPOD at the center) after eight weeks of supplementation.
Conclusion: We report significant increases in serum concentrations of MZ and L following supple-
mentation with MZ, L, and Z and a significant increase in MPOD, including its spatial profile, after 
two weeks of supplementation. Also, this study has detected the possible presence of MZ in human 
serum pre-supplementation and the ability of the study carotenoid formulation to rebuild central 
MPOD in subjects who have atypical profiles at baseline.
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 blindness in developed countries.1,2 It is estimated that 
the number of people suffering from AMD will continue 
to increase, primarily due to increasing longevity.3,4 It is 
now believed that both oxidative stress and cumulative 
exposure to short-wavelength (blue) light are involved 
in the aetiopathogenesis of AMD.5–7
The center of the retina has a distinct yellow color 
attributable to the presence of a pigment known as 
macular pigment (MP), and this coloration contrib-
uted to the original eponymous description of this 
retinal region as the macula lutea (or yellow spot).8,9 MP 
comprises three dietary carotenoids meso- zeaxanthin 
(MZ), lutein (L), and zeaxanthin (Z).8–10 There is now 
a biologically plausible rationale, supported by a 
growing body of evidence, in support of the view 
that MP protects against AMD.7 For example, MP 
has been shown to significantly reduce the amount 
of blue light incident on the macula.11–14 Furthermore, 
the  antioxidant properties of MP′s constituent caro-
tenoids within the retina and elsewhere have been 
demonstrated in vitro.15,16
L and Z are found in a typical western diet, in fruit 
and vegetables (e.g., spinach, corn, orange peppers, 
red grapes);17 whereas, MZ is believed to be generated 
at the macula following a biochemical  transformation 
of L.18,19 MZ has also been identified in some less 
 commonly consumed foods including fish (e.g., 
salmon and trout), shrimp, and turtle fat20; however, 
to date and in the absence of supplementation with this 
carotenoid, MZ has not been detected or reported in 
human serum. From a scientific perspective, we were 
interested to investigate how individuals respond to 
an MZ-based supplement (even in combination with 
the other macular carotenoids) as it has been reported 
that there is an association between AMD and MP 
profile21 and given that research has shown that MZ 
is  generated in the retina following L conversion. It 
is possible that individuals lacking centrally located 
MP require MZ to be provided in supplement form, 
as such individuals could (perhaps) lack the capacity 
to convert L to MZ within the retina.
There are several published studies reporting on 
supplemental L and/or Z, and the impact of such 
supplementation on MP levels and/or serum con-
centrations of these carotenoids (Table 1). In 1997, 
Hammond et al. showed that a diet modified to 
result in increased consumption of L and Z, for as 
little as four weeks, could augment MP, with this 
effect being maintained for several months follow-
ing resumption of a normal, unmodified diet.22 Of 
note, two of the 11 subjects involved in that study 
did not show a significant rise in MP optical density 
(MPOD), despite a significant increase in serum L 
concentrations. These subjects were termed “retinal 
non-responders”, and it has been hypothesized that 
this phenomenon may be due to a compromised 
ability to capture and/or  stabilize the macular 
carotenoids in these individuals.7 Landrum et al. 
investigated the effect of L supplementation (30 mg 
per day) in two individuals over a 140-day  period.23 
They found an increase in serum L concentrations 
in both individuals, coupled with a parallel increase 
in MPOD. A more recent investigation reporting on 
a commercially available L-based supplement with 
respect to macular and serum response in patients 
who displayed features of AMD was performed by 
Trieschmann et al. in 2007.24 In that study, the authors 
concluded that supplementation with 12 mg of L and 
1 mg of Z, combined with co-antioxidants, resulted 
in a significant increase in MPOD at 0.5° eccentricity 
and in the majority of subjects (average increase ∼ 0.1 
optical density units [ODU]).
Of note, there has only been one study to date 
which investigated the effects of supplemental MZ on 
MPOD levels in human subjects.25 That study, which 
included 10 subjects, showed that a soya bean oil-
based supplement containing 14.9 mg of MZ, 5.5 mg 
of L, and 1.4 mg of Z resulted in an average increase 
of ∼ 0.07 MPOD at 0.75° of eccentricity over a 120 
day period.25 However, limitations of the study per-
formed by Bone et al. include: MPOD was measured 
at only one point of retinal eccentricity (∼ 0.75°) and 
would therefore not have been able to detect changes 
in MPOD, if any, occurring at other retinal eccentrici-
ties (e.g., 0.25°, 0.5°, 1°, 1.75°), including the more 
central eccentricities of 0.25° and 0.5°; no controls 
were included in the study; small sample size (n = 10); 
and serum concentrations of MZ was only measured 
for two subjects.
Our study, the Meso-zeaxanthin Ocular Supplemen-
tation Trial (MOST), was designed to evaluate MPOD 
response, including its spatial profile (i.e., 0.25°, 0.5°, 
1°, and 1.75°), and serum carotenoid response, in 10 
subjects (five normal and five AMD), following con-
sumption of a dietary food supplement containing 
all three macular carotenoids: MZ, L, and Z, in which 
MZ was the predominant carotenoid. The limitations 
of this pilot investigation are as follows: no controls 
were included into the study; small sample size 
(n = 10); however, the entire spatial profile of MPOD 
was assessed (see above) and serum concentrations of 
MZ were analyzed for all 10 subjects.
METHODS
Subjects
This was a non-randomized and open labeled study. 
All subjects signed an informed consent document 
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TABLE 1 Studies reporting on macular pigment optical density response to supplementation with the macular carotenoids
Principal author Year Journal Tech No. Age
L  
(mg/day)
Z  
(mg/day)
MZ  
(mg/day)
Duration 
(weeks)
Retinal 
 eccentricity
MP 
increase PF Significance
Normal subjects—dietary modification
Hammond et al. 1997 IOVS HFP 10 30–65 11.2 0.6 0 15 0.5° ∼ 0.05 5.5° p < 0.05
Hammond et al. 1997 IOVS HFP 2 30–65 0.4 0.3 0 15 0.5° ∼ 0.05 5.5° -
Hammond et al. 1997 IOVS HFP 1 30–65 10.8 0.3 0 15 0.5° ∼ 0.05 5.5° p < 0.05
Johnson et al. 2000 AJCN HFP 7 33–54 11.2 0.57 0 15 0.5° ∼ 0.07 5.5° p < 0.05
NORMAL subjects—supplement modification
Landrum et al. 1997 EER HFP 2 42–51 30 0 0 20 0.75° ∼ 0.20 8° -
Berendschot et al. 2000 IOVS SLO 8 18–50 10 0 0 12 0.75° ∼ 0.05 14° p = 0.022
Berendschot et al. 2000 IOVS SA 8 18–50 10 0 0 12 0.75° ∼ 0.04 - p < 0.001
Aleman et al. 2001 IOVS HFP 8 11–59 20 0 0 24 0.17° 0.07 5-7° p = 0.04
Aleman et al. 2001 IOVS HFP 8 11–59 20 0 0 24 0.5° 0.07 5-7° -
Aleman et al. 2001 IOVS HFP 8 11–59 20 0 0 24 1° 0.08 5-7° -
Aleman et al. 2001 IOVS HFP 8 11–59 20 0 0 24 2° 0.04 5-7° -
Bone et al. 2003 JN HFP 2 19–59 30 1.5 0 20 0.75° ∼ 0.20 8° -
Bone et al. 2003 JN HFP 1 53 0 30 0 17 0.75° ∼ 0.07 8° -
Bone et al. 2003 JN HFP 21 19–59 2.4 0 0 17 0.75° ∼ 0.04 8° -
Bone et al. 2003 JN HFP 12 19–60 20 0 0 17 0.75° ∼ 0.06 8° p < 0.05
Bone et al. 2003 JN HFP 2 26–27 5 0 0 17 0.75° ∼ 0.03 8° -
Koh et al. 2004 EER HFP 6 64–81 20 0 0 20 0.5° 0.07 6° p > 0.05
Bernstein et al. 2004 ABB HFP 8 <61 20 0 0 16 0.75° 0.04 8° -
Bernstein et al. 2004 ABB RRS 8 <61 20 0 0 16 - 76RC - -
Bone et al. 2007 NM HFP 10 21–58 5.5 1.4 14.9 17 0.75° ∼ 0.07 8° p < 0.05
Wenzel et al. 2007 OPO HFP 3 24–52 30 2.7 0 17 0.33° 0.07 7° p < 0.001
Wenzel et al. 2007 OPO HFP 3 24–52 30 2.7 0 17 0.5° 0.07 7° p < 0.002
Wenzel et al. 2007 OPO HFP 3 24–52 30 2.7 0 17 1° 0.046 7° p< 0.002
Wenzel et al. 2007 OPO HFP 3 24–52 30 2.7 0 17 2° 0 7° -
Schalch et al. 2007 ABB HFP 23 18–45 10.7 0.8 0 17 0.5° 0.06 5.5° p = 0.04
Schalch et al. 2007 ABB HFP 23 18–45 0 12.6 0 17 0.5° 0.01 5.5° p > 0.1
Schalch et al. 2007 ABB HFP 23 18–45 10.2 11.9 0 17 0.5° 0.06 5.5° p = 0.04
Johnson et al. 2008 AJCN HFP 11 60–80 12 0.5 0 16 1.5° - 7° p < 0.05
Johnson et al. 2008 AJCN HFP 11 60–80 12 0.5 0 16 3° - 7° p < 0.01
Stringham et al. 2008 OVS HFP 40 17–41 10 2 0 24 0.25° 0.19 10 -
Stringham et al. 2008 OVS HFP 40 17–41 10 2 0 24 0.5° 0.16 10 -
Stringham et al. 2008 OVS HFP 40 17–41 10 2 0 24 1° 0.1 10 -
Stringham et al. 2008 OVS HFP 40 17–41 10 2 0 24 3° 0.07 10 -
Stringham et al. 2008 OVS HFP 40 17–41 10 2 0 24 7° 0.03 10 -
AMD subjects
Principal author Year Journal Tech No. Age
L  
(mg/day)
Z  
(mg/day)
MZ  
(mg/day)
Duration 
(weeks)
Retinal 
 eccentricity
MP 
increase PF Significance
Koh et al. 2004 EER HFP 7 64-81 20 0 0 20 1° 0.07 6° p > 0.05
Trieschmann et al 2007 EER AF 108 51-87 12 1 0 24 1° 0.1 6° p < 0.0008
Richer et al. 2007 OPT HFP 76 - 10 0 0 52 1° 0.25 7° p < 0.05
MPOD = macular pigment optical density; L = Lutein (mg/day); Z = Zeaxanthin (mg/day); MZ = Meso-zeaxanthin (mg/day); 
Tech = technique used to measure MPOD; No. = Number of subjects participating in study; Age = Age range of subjects in study; 
PF = Parafovea stimulus; AJCN = American Journal of Clinical Nutrition; IOVS = Investigative Ophthalmology and Visual Science; 
ABB = Archives of Biochemistry and Biophysics; OPO = Ophthalmic and Physiological Optics; EER = Experimental Eye Research; 
NM = Nutrition and Metabolism; OPT = Optometry; JN = Journal of Nutrition; OVS = Optometry and Vision Science; RC = Raman 
counts; ODU = Optical density units; HFP = Heterochromatic flicker photometry; AF = Autofluorescence; SLO = Scanning Laser 
ophthalmoscope; SA = Spectral Analysis; AMD = Age related Macular Degeneration; RRS = Resonance Raman Spectroscopy; - = data 
unavailable.
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and the experimental measures conformed to the 
Declaration of Helsinki. The study was reviewed and 
approved by the Research Ethics Committee, South 
East Region, Waterford Regional Hospital, Waterford, 
Ireland.
This study consisted of two groups; Group 1 (n = 5), 
inclusion criteria: male or female between the age 
of 18 and 60 years; no presence of ocular pathology; 
visual acuity of at least 6/18 in the study eye. Exclu-
sion criteria: individuals outside age range 18–60 years; 
pregnancy; presence of ocular pathology; currently 
taking supplements containing MZ, L, or Z. Group 2 
(n = 5), inclusion criteria: male or female; early AMD 
(defined using the International Classification and 
Grading System for Age-Related Maculopathy and 
Age-Related Macular Degeneration)26 in at least one 
eye with best corrected visual acuity of at least 6/18 
in that eye, hereafter known as the study eye for this 
group. Exclusion criteria: currently taking supplements 
containing MZ, L, or Z; presence of ocular pathology 
other than AMD.
The mixture of carotenoids was manufactured by 
Industrial Organica SA, Monterrey, Mexico by isomer-
izing L obtained from marigold extracts. A proportion 
of the L was converted into MZ, and the small quantity 
of Z in the extract remained unchanged. The resulting 
composition was microencapsulated after diluting with 
rice starch. Each capsule contained 7.3 mg MZ, 3.7 mg 
L, and 0.8 mg Z. We used a carotenoid formulation con-
taining high amounts of MZ, as this carotenoid is now 
commercially available and reports on its response in 
human subjects, to date, are limited. In addition, we 
now present a scientific rationale for supplementation 
with this carotenoid in our Introduction (see page 000, 
paragraph 1).
All subjects (in both groups) were instructed to take 
one capsule per day with a meal for 60 days. MPOD, 
including its spatial profile (i.e., 0.25°, 0.5°, 1°, 1.75°), 
was measured at baseline and at two week intervals 
(V1: Baseline; V2: 2 weeks; V3: 4 weeks; V4: 6 weeks; 
V5: 8 weeks) over the 60 days (see Method below). In 
Group 1, the eye with better visual acuity was chosen 
as the study eye; however, where both eyes had the 
same corrected acuity, the right eye was chosen as the 
study eye.
A blood sample was collected at each study visit for 
serum carotenoid analysis of MZ, L, and Z (see Meth-
ods below). Demographic, lifestyle, and vision infor-
mation was also collected from each subject as follows: 
name, contact information, age, sex, BMI, smoking 
habits, lifestyle, medication, and vision history. Best 
corrected visual acuity (BCVA) was measured using 
logMAR.
Serum Total L and Total Z analysis—Assay 1
Blood samples (6–8 mL) were collected from all patients 
on the same day as MPOD assessment. Serum was 
separated from blood by centrifugation (DESAGA 
Starstedt–Gruppe, GC12) 2500 RPM for 10 min, and 
then aliquoted into two amber light-sensitive micro-
centrifuge tubes and stored at minus 70°C until time of 
analysis. A 400 μL aliquot of serum was pipetted into 
an amber light-sensitive microcentrifuge tube (1.5 mL 
total capacity). Ethanol (300 μL) containing 0.25 g/L 
butylated hydroxytoluene (BHT) and 200 μL internal 
standard (α-tocopherol acetate [0.25 g/L]) were added 
to each tube. Heptane (500 μL) was then added and 
samples were vortexed vigorously for 2 min followed by 
centrifugation at 2000 rpm for 5 min (MSC Micro Cen-
taur, Davison & Hardy Ltd., Belfast, UK). The resulting 
heptane layer was retained and transferred to a second 
labeled amber light-sensitive microcentrifuge tube, 
and a second heptane extraction was performed. The 
combined heptane layers were immediately evaporated 
to dryness under nitrogen. These dried samples were 
reconstituted in 200 μL methanol (containing 0.25 g/L 
BHT), and 100 μL was injected for high-performance 
liquid chromatography (HPLC) analysis.
We used an Agilent 1200 series (Agilent Technologies 
Ltd., Dublin, Ireland) system with photodiode array 
detection at a wavelength of 450 nm. A 5 μm analyti-
cal/preparative 4.6 × 250 mm 201TP speciality reverse 
phase column (Vydac, Hesperia, California, USA) was 
used with an in-line guard column. The mobile phase 
consisted of 97% methanol and 3% tetrahydrofuran. 
The flow rate was 1 mL/min, and the total run time 
was 15 min.
DSM Nutritional Products (Basel, Switzerland) pro-
vided total L (TL) and total Z (TZ) standards to gener-
ate response factors that were used to calculate serum 
concentrations of TL and TZ. An internal standard, 
α-tocopherol acetate, made up in ethanol (0.25 mg/L) 
was used to correct for recovery of extractions for 
HPLC analysis and assist quantification. All chromato-
grams were integrated manually by drawing a base-
line and dropping perpendicular lines to quantify the 
peaks of interest (Figure 1A). All carotenoid peaks were 
integrated and quantified using Agilent ChemStation 
software. Figure 1A shows a typical chromatogram 
generated from the above described assay.
Serum MZ Analysis—Assay 2
Assay 1 outlined above resulted in separation of TL 
and TZ. The eluent that corresponded to the peak of 
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TZ from assay 1 was collected from the waste line 
(fraction 1) and evaporated to dryness under nitro-
gen. Fraction 1 also contained some TL, as TL and 
TZ eluted close together, which made it difficult to 
collect just TZ from the waste line. All dried down 
samples were then reconstituted in 50 μL of n-hexane-
isopropanol (90:10) and 40 μL was injected onto the 
10 μm Chiralpak™ AD column (250 × 4.6 mm; Chiral 
Technologies Europe, France) protected by a Chiral-
pak™ guard column and a 2 μm filter. In order to 
achieve separation of the Z isomers (Z and MZ), a 
flow rate of 0.8 mL/min with the following gradient 
elution: starting at 90% n-hexane and 10% isopropa-
nol, and increasing to 95% n-hexane over 30 min was 
used.27 Integration was manually carried out on the 
resulting chromatogram from assay 2 by drawing a 
baseline between ∼13 and ∼30 min and then dropping 
a perpendicular line to quantify the proportions of Z 
and MZ from their peak areas. The proportions of the 
Z isomers were assumed to be the same as in the TZ 
fraction from the column of assay 1, which enabled 
calculation of the individual amounts of Z and MZ in 
the TZ fraction. A sample chromatogram showing the 
MZ and Z peaks is presented in Figure 1B.
Macular Pigment Optical Density
MPOD was measured using the Macular Metrics Den-
sitometer™, developed by Professor B. R. Wooten of 
Brown University, Providence, Rhode Island, USA, 
using heterochromatic flicker photometry (HFP). The 
Total Zeaxanthin
Total Lutein
mAU
15
12.5
10
7.5
5
2.5
0
0 2 4 6 8 10 12 min
−2.5
FIGURE 1A Chromatogram showing lutein and zeaxanthin peaks obtained from assay 1 using high 
 performance liquid chromatography as follows. Column: 5 micron analytical/preparative 4.6 × 250 mm 
201TP speciality reverse phase; detector: photo diode array and UV; wavelength: 450 nm; mobile phase: 97% 
 methanol and 3% tetrahydrofuran; run time: 15 min; elution: isocratic. All peaks were integrated manually 
using Chemstation software.
Meso-zeaxanthin
Zeaxanthin
Lutein
0.75
0.25
0
0 5 10 15 20 25 30 35 min
mAU
1.75
1.5
1.25
1
0.5
FIGURE 1B Chromatogram showing zeaxanthin isomer peaks (1 and 2) obtained from assay 2. 
Peak 3 is a lutein peak collected into fraction 1. The eluate also contained some TL, as TL and 
TZ were not baseline separated in the first fractionation; therefore, it is not possible to collect 
just TZ from the waste line. The method used is as follows. Column: Chiralpak™ AD column 
(250 × 4.6 mm); detector: diode array; wavelength: 450 nm; mobile phase: isopropanol and 
n-hexane; run time: 30 min; elution: gradient, starting at 90% n-hexane and 10% isopropanol, 
increasing to 95% n-hexane. All peaks were integrated manually using Chemstation software.
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device was modified from the one described original-
ly.28 Two different techniques for measuring MPOD 
using this device were employed for normal subjects 
(Group 1—“method of adjustment”) and AMD subjects 
(Group 2—“bracketing method”), and are described 
below. We used the bracketing procedure for the AMD 
subjects as we find this procedure more suitable for 
older subjects (see below). All subjects were trained 
how to perform the HFP task at their first study visit. 
MPOD data was not recorded until subjects demon-
strated a high level of understanding of the task. Reli-
ability and reproducibility of MPOD measurements 
obtained using the Macular Metrics Densitometer™ 
have previously been reported.29,30
Background Common to Both Techniques
In order to measure MPOD, the subject views a 
stimulus that alternates between a wavelength band 
absorbed by MP and one that is not. The radiance of 
the wavelength band absorbed by MP is adjusted in 
order to minimize the subjects′ percept of flicker. The 
range of alternation rates where flicker is not perceived 
is called the null zone. Primarily because of inter-indi-
vidual differences in temporal (e.g., flicker) sensitivity, 
it is optimal to customize the HFP task for each subject 
by selecting the alternation rate to achieve a null zone 
and a precise setting. This has been termed as custom-
ized HFP (cHFP).31
The first methodological consideration when using 
cHFP is selecting the appropriate flicker rate. Select-
ing the best flicker rate for each subject enables one to 
accommodate the variation in flicker sensitivity due to 
factors such as age and disease.32,33 If differences among 
subjects in flicker sensitivity are not accounted for (i.e., 
a fixed flicker frequency is used), then a subject with 
low flicker sensitivity (i.e., low critical flicker fusion 
frequency—CFF) will most likely experience a large 
null flicker zone. Alternatively, a subject with a high 
CFF may not be able to eliminate flicker from the test 
target, which would make the task difficult to com-
plete.
Predicted optimal HFP flicker frequencies were esti-
mated in order to facilitate good subject performance 
and reduce measurement error. To achieve this, we 
used an age-guided algorithm to estimate optimal HFP 
flicker frequencies for all the measurements performed 
(i.e., the measurement locus at 0.25°, 0.5°, 1°, 1.75°, and 
reference locus at 7°). This algorithm was informed by 
many years′ experience with the Densitometer™ at 
several different laboratories (see Table 2).
The second methodological consideration involves 
a test stimulus configuration in which the radiances 
of the two alternating components are inverse-yoked. 
In other words, when the blue component is adjusted 
to be more intense, the luminance of the green compo-
nent is commensurately decreased, and vice versa. This 
procedure keeps the brightness of the test stimulus 
relatively constant. This approach is regarded as an 
improvement because some subjects find changes in 
brightness distracting when they perform the task.
In this study we measured the spatial profile of 
MP at four different retinal eccentricities: 0.25°, 0.5°, 
1°, and 1.75° with a reference point at 7°. The targets 
and fixation points used for each retinal eccentricity 
measured were as follows: the 0.25° and 0.5° eccentrici-
ties were measured using a 0.5° and 1° diameter disc 
with a 5 min black fixation point at the center; the 1° 
and 1.75° eccentricities were measured using a 20 min-
wide annuli with mean radii corresponding to those 
eccentricities were used with a centrally fixated 5 min 
black fixation point. The 7° reference measurement was 
a 2° diameter disc located 7° nasally with reference to 
a 5 min red fixation point (Figure 2). For the purpose 
of this study, we assume that flicker perception is 
dominated by the edges of the disc-shaped stimuli 
used in each instrument, although other research has 
suggested that this may not be the case.34
Group 1—Method of Adjustment
Prior to MP measurement, subjects were shown a 
video that described the task in hand, with instruc-
tions. The first measurement of MP was carried out 
at 0.5° retinal eccentricity. The subject was instructed 
to place his/her study eye at the viewing eyepiece 
and the examiner ensured that the tilt of the main 
unit allowed comfortable viewing for the subject. The 
appropriate flicker frequency was set for the subject′s 
age. The examiner set the radiance button all the way 
to the left (i.e., lowest blue light intensity) or right (i.e., 
highest blue light intensity). The subject then pushed 
the first of the radiance control buttons (on the left 
TABLE 2 Predicted optimal flicker frequency for 
 densitometer™ targets
Age OFF 0.25° OFF 0.5°, 1°, 1.75° OFF 7°
18–20 18 19 13
21–30 18 19 12
31–40 17 18 11
41–50 15 16 10
51–60 13 14 9
61–70 12 13 8
71–80 11 12 7
81+ 10 11 6
OFF = optimal flicker frequency; 0.25° = MPOD measured at 
0.25° retinal eccentricity; 0.5° = MPOD measured at 0.5° retinal 
eccentricity; 1° = MPOD measured at 1° retinal eccentricity; 
1.75° MPOD = MPOD measured at 1.75° retinal eccentricity; 
7° = MPOD measured at 7° retinal eccentricity. This algorithm 
developed by Nolan and Stringham was used to estimate opti-
mal HF{ flicker frequencies for each retinal locus, including the 
reference locus.
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of the control pad) that electronically, smoothly and 
continuously altered the blue/green ratio until the 
beginning of the null flicker zone was reached. The 
subject continued to hold down the button until the 
end of the null flicker zone was reached. Once the null 
flicker zone had been defined, the subject used the sec-
ond radiance control button (on the right) to go back 
through the no flicker zone. The subject then used 
both radiance control buttons to go back and forth 
through the null flicker zone until the center of the 
zone (i.e., their null flicker point) was identified, and 
the radiance value at this point was then recorded by 
the examiner. After each measurement, the examiner 
offset the radiance button to a random position and 
the subject repeated the test as above. This procedure 
was repeated on four more occasions and the radiance 
values were recorded in the MPOD log form. The same 
procedure was repeated for measurements (see above) 
at the following retinal eccentricities 0.25°, 1°, 1.75°, 7° 
(Figure 2). MPOD was then calculated using the log 
ratio of the measurement radiance values with respect 
to the reference radiance values obtained for each 
subject at 7°, using a method of adjustment MPOD 
calculator provided by Macular Metrics (Providence, 
Rhode Island, USA).
Of note, if the subject reported that there was no 
null flicker zone, the examiner increased the flicker 
frequency by two Hz. If the subject reported a very 
wide null zone then the flicker frequency was reduced 
by two Hz. These steps were repeated if necessary.
Bracketing Method—Group 2
The “bracketing method” developed by members 
of the Macular Pigment Research Group, Waterford, 
Ireland (Dr. John M. Nolan, Dr. Edward Loane) and 
Professor B.R. Wooten of Brown University, US (Den-
sitometer™ inventor), allowed us to obtain quick, but 
accurate and customized, MPOD values for Group 2 
and is described below.
A diagrammatic representation of the initial test 
stimulus was used to familiarize the subject with the 
nature of the task (Figure 2). The examiner selected the 
target required to measure MPOD at 0.5° eccentricity 
(1° stimulus (Figure 2)). The subject was instructed to 
place his/her study eye at the viewing eyepiece and the 
examiner ensured that the tilt of the main unit allowed 
comfortable viewing for the subject. The appropriate 
flicker frequency was set for the subject′s age. The 
examiner set the radiance button all the way to the left 
(i.e., lowest blue light intensity). The examiner then 
pushed a button that electronically, smoothly and con-
tinuously altered the blue/green ratio until the subject 
reported that there was no flicker. The radiance value 
obtained was recorded and this same procedure was 
repeated on four more occasions and recorded in the 
MPOD log form. The examiner set the radiance button 
all the way to the right (i.e., highest blue light intensity) 
and repeated the test four times as above. This com-
pleted the first part of the measurement (ten radiance 
values obtained in total, five approaching from the 
lowest blue light intensity and five approaching from 
highest blue light intensity). The same procedure was 
repeated for measurements (see above) at the follow-
ing retinal eccentricities 0.25°, 1°, 1.75°, 7°, and MPOD 
was calculated using the log ratio of the measurement 
radiance values with respect to the reference radiance 
values obtained for each subject at 7°, using a bracket-
ing procedure MPOD calculator provided by Macular 
Metrics (Providence, Rhode Island, USA).
Stimulus
1
Fixation Fixation
Stimulus
2
Stimulus
Fixation
3
Stimulus
Fixation
4
Stimulus
Fixation
5
FIGURE 2 MPOD = macular pigment optical density; Fixa-
tion = fixation point for stimulus; Stimulus = stimulus viewed 
by subject; 1 = target used to measure MPOD at 0.25° retinal 
eccentricity (stimulus diameter = 0.5° disc); 2 = target used to 
measure MPOD at 0.5° retinal eccentricity (stimulus diam-
eter = 1° disc); 3 = target used to measure MPOD at 1° retinal 
eccentricity (stimulus diameter = 20 min annulus with mean 
radius corresponding to 1°); 4 = target used to measure MPOD 
at 1.75° retinal eccentricity (stimulus diameter = 20 min annu-
lus with mean radius corresponding to 1.75°); 5 = target used 
to measure MPOD at 7° retinal eccentricity (stimulus diam-
eter = 2° disc with reference to a red fixation point at 7°).
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Previous models of the densitometer (and most other 
similar devices) control the blue/green energy ratio 
with a rotary dial. Thus, the subject (if using method of 
adjustment) or the examiner (if using bracketing) turn 
the dial until the desired point of null flicker is reached. 
This works well for most subjects. However, some are 
prone to adjust the dial much too slowly. Others, on 
the other hand, make their adjustments too quickly. In 
the bracketing procedure, there are individual differ-
ences in the way different examiners control the dial. 
The current version of the densitometer avoids these 
potential sources of variability by substituting the dial 
with two push buttons: one button when depressed 
and held down causes the blue/green ratio to increase, 
whereas the other causes the blue/green ratio to 
decrease. Unlike a subject or examiner turning a dial, 
the rate of blue/green change is controlled entirely by 
the densitometer′s electronics and was determined to 
be optimal (neither too fast or too slow) at 7 sec for a 
sweep from one extreme to the other of the blue/green 
ratio. Preliminary studies have shown that this new 
procedure not only removes the aforementioned vari-
ability, but the task is qualitatively easier for the sub-
jects. Although the bracketing method was introduced 
to aid ease of use, there was one AMD subject (subject 
10) who was unable to complete the test, despite sev-
eral attempts to explain the procedure. Results from 
this subject were unreliable (i.e., repeated measures or 
variation within measurement greater than 10%) and 
were therefore excluded from all MPOD analysis and 
presentation.
Statistical Analysis
The statistical software package SPSS (version 17) was 
used for analysis and SigmaPlot (version 8.0) was used 
for graphical presentations. Between group differences 
(Normal [Group 1] vs. AMD [Group 2] in age, BMI, 
baseline serum carotenoid concentration and baseline 
MPOD levels [Table 2]) were investigated using inde-
pendent samples t-tests. Between group differences in 
sex were investigated using the standard Chi square 
test. Pearson correlation coefficient analyzes were con-
ducted to investigate the relationship between bivari-
ables. All quantitative variables investigated exhibited 
a typical normal distribution. Means ± SDs are pre-
sented in the text and tables. We conducted repeated 
measures analysis of variance for MPOD, including its 
spatial profile, and serum concentrations of MZ, TL, 
TZ, and Z measured at each of five study visits using 
a general linear model approach. Differences between 
two time points, within subjects, were assessed using 
paired samples t-test. We used the 5% level of signifi-
cance throughout our analysis.
RESULTS
The demographic, lifestyle, baseline macular serum 
carotenoid concentrations, and baseline MPOD data 
for the entire study group, Normal subjects (Group 1) 
and AMD subjects (Group 2) are presented in Table 3. 
As seen from this table, age was the only variable for 
which a statistically significant between group differ-
ence was observed (p = 0.001).
Alterations in Serum Macular Carotenoid 
Concentrations Following Supplementation
We conducted a repeated measures analysis of variance 
for serum concentrations of MZ, TL, TZ, and Z quan-
tified at each of the five study visits using a general 
linear model approach. The results are summarized in 
Table 4; the p values displayed in the final column of 
this table were obtained using the Huynh-Feldt cor-
rection for sphericity. Use of the more conservative 
Greenhouse-Gesser correction would have led, in all 
cases, to the same conclusions regarding statistical sig-
nificance. It is clear from Table 4 and the mean plots 
of Figures 3, 4, and 5 that the serum concentrations 
of MZ, TL, and TZ increase significantly with time; 
whereas, there was no significant time effect for serum 
concentrations of Z (p = 0.909) (Table 4, Figure 6). Post 
hoc analysis (paired samples t-tests) revealed that the 
significant increase from baseline was present after two 
weeks of supplementation (TL: p < 0.05; TZ: p < 0.05, 
and MZ: p = 0.01). The data for each individual subject 
are presented in Table 5.
Alterations in the Spatial Profile of 
MPOD Following Macular Carotenoid 
 Supplementation
We conducted a repeated measures analysis of vari-
ance for MPOD (at 0.25°, 0.5°, 1°, 1.75°, and average 
MPOD for all these eccentricities) measured at each 
of the five study visits using a general linear model 
approach. The results are summarized in Table 6; the 
p values displayed in the final column of this table 
were obtained using the Huynh-Feldt correction for 
sphericity. Use of the more conservative Greenhouse-
Gesser correction would have led, in all cases, to the 
same conclusions regarding statistical significance. It 
is clear from Table 7 and the mean plots of Figure 7 
that MPOD at 0.25°, 1° and average MPOD across the 
retina all increase significantly with time; whereas, 
there was no significant time effect for MPOD at 0.5° 
and 1.75° throughout the study period (p = 0.101 and 
p = 0.61). Of note, the biggest increase seen in MPOD 
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was nearest the center (i.e., at eccentricity 0.25°) (see 
Table 6 and Figure 7).
Post hoc analysis (paired samples t-tests) revealed 
that a significant increase from baseline was present 
after two weeks of supplementation (p < 0.005, for all), 
with the exception of MPOD at 1.75°, which was signifi-
cantly different from baseline only at V3 (p = 0.004). The 
data for each individual subject is presented in Table 7.
TABLE 3 Baseline characteristics for Group 1 and Group 2
Characteristic Entire group Group 1 Group 2 p-Value
Age 53 ± 21 35 ± 9 72 ± 11 p = 0.001
Sexa 5 M, 5 F 2 M, 3 F 3 M, 2 F p = 0.527
BMI 27 ± 4 24.8 ± 1.8 29.4 ± 4.3 p = 0.075
Serum TLb 0.302 ± 0.103 0.314 ± 0.086 0.290 ± 0.126 p = 0.728
Serum TZc 0.131 ± 0.070 0.169 ± 0.78 0.093 ± 0.036 p = 0.082
Serum MZd 0.023 ± 0.007 0.022 ± 0.005 0.023 ± 0.009 p = 0.735
Serum Ze 0.108 ± 0.067 0.147 ± 0.74 0.070 ± 0.030 p = 0.063
0.25° MPOD 0.39 ± 0.19 0.45 ± 0.17 0.30 ± 0.20 p = 0.245
0.5° MPOD 0.38 ± 0.16 0.44 ± 0.13 0.30 ± 0.17 p = 0.205
1° MPOD 0.26 ± 0.15 0.30 ± 0.10 0.23 ± 0.21 p = 0.519
1.75° MPOD 0.14 ± 0.10 0.12 ± 0.08 0.17 ± 0.14 p = 0.556
Average MPOD 0.29 ± 0.13 0.33 ± 0.09 0.25 ± 0.18 p = 0.399
aM = male, F = female.
bTotal lutein (μmol/L).
cTotal zeaxanthin (μmol/L).
dMeso-zeaxanthin (μmol/L).
eZeaxanthin (μmol/L).
Mean ± SD; Group 1 = normal subjects; Group 2 = AMD subjects (Age-related Macular Degeneration); BMI = body mass index; 
MPOD = macular pigment optical density; 0.25° MPOD = MPOD measured at 0.25° retinal eccentricity; 0.5° MPOD = MPOD mea-
sured at 0.5° retinal eccentricity; 1.0° MPOD = MPOD measured at 1.0° retinal eccentricity; 1.75° MPOD = MPOD measured at 1.75° 
retinal eccentricity; Average MPOD = average MPOD of all degrees of retinal eccentricity (0.25°, 0.5°, 1.0°, and 1.75 degrees of retinal 
eccentricity).
TABLE 4 Average serum results for all subjects at each study visit
 V1 V2 V3 V4 V5 p-Value
Total lutein 0.30 ± 0.1 0.36 ± 0.12 0.40 ± 0.14 0.37 ± 0.12 0.36 ± 0.12 p = 0.002
Total zeaxanthin 0.13 ± 0.07 0.16 ± 0.06 0.18 ± 0.07 0.16 ± 0.05 0.17 ± 0.06 p = 0.003
Meso-zeaxanthin 0.02 ± 0.01 0.06 ± 0.02 0.07 ± 0.03 0.06 ± 0.02 0.06 ± 0.03 p = 0.000
Zeaxanthin 0.11 ± 0.07 0.10 ± 0.05 0.11 ± 0.05 0.10 ± 0.04 0.11 ± 0.04 p = 0.909
Values represent mean ± SD in μmol/L; N = 10; V1 = visit 1, V2 = visit 2, V3 = visit 3, V4 = visit 4, V5 = visit 5. The p-values represent 
repeated measures ANOVA for the 5 study visits, with Huynh-Feldt corrections for lack of sphericity.
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FIGURE 3 Mean (± standard error) serum total lutein concen-
trations for 10 subjects over the 8-week study period.
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FIGURE 4 Mean (± standard error) serum total zeaxanthin 
concentrations for 10 subjects over the 8-week study period.
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The Relationship between Alterations in 
MPOD Spatial Profile and Alterations in 
Serum Carotenoid Concentrations
In this study, the following all showed significant 
increases with time: serum MZ, serum TL, and serum 
TZ, MPOD at eccentricities at 0.25°, 1°, and also aver-
age MPOD across the retina (i.e., 0.25°, 0.5°, 1°, 1.75°) 
(see repeated measures results above, Figures 3, 4, 5, 
and Tables 4 and 6, respectively).
However, investigating change in serum concen-
trations (for V2-V1) in each of MZ, TL, and TZ with 
respect to change in MPOD at 0.25°, 1°, and average 
MPOD, we found that, in every case, there is an 
inverse correlation between these variables (r = -0.538 
to -0.805, e.g., V2-V1 serum concentrations of MZ vs. 
V2-V1 MPOD at 0.25°: r = -0.538, p = 0.135, Figure 8A). 
The fact that some of these correlations were not statis-
tically significant can be ascribed to the small sample 
size of the current study. Of note, the strongest inverse 
Time (weeks)
0 2 4 6 8 10
S
er
um
 M
es
o-
ze
ax
an
th
in
 (µ
m
ol
/L
)
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
FIGURE 5 Mean (± standard error) serum meso-zeaxanthin 
concentrations for 10 subjects over the 8-week study period.
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FIGURE 6 Mean (± standard error) serum zeaxanthin con-
centrations for 10 subjects over the 8-week study period.
TABLE 5 Individual serum concentrations for total lutein, total zeaxanthin, meso-zeaxanthin, and zeaxanthin at each study visit
S Group
V1 V2 V3 V4 V5
L ZT MZ Z L ZT MZ Z L ZT MZ Z L ZT MZ Z L ZT MZ Z
1 Normal 0.30 0.18 0.03 0.15 0.29 0.17 0.03 0.13 0.34 0.22 0.06 0.17 0.34 0.21 0.06 0.14 0.33 0.18 0.07 0.11
2 Normal 0.25 0.13 0.02 0.11 0.36 0.18 0.07 0.11 0.37 0.20 0.08 0.12 0.25 0.14 0.03 0.11 0.25 0.12 0.03 0.09
3 Normal 0.29 0.13 0.02 0.11 0.35 0.15 0.05 0.11 0.32 0.14 0.06 0.08 0.34 0.16 0.07 0.09 0.31 0.14 0.04 0.10
4 Normal 0.27 0.11 0.02 0.09 0.46 0.23 0.09 0.13 0.59 0.23 0.11 0.12 0.45 0.20 0.08 0.12 0.55 0.24 0.12 0.12
5 Normal 0.46 0.30 0.03 0.27 0.55 0.28 0.08 0.20 0.62 0.32 0.11 0.21 0.51 0.27 0.09 0.18 0.49 0.27 0.07 0.20
6 AMD 0.49 0.14 0.03 0.11 0.55 0.18 0.07 0.11 0.58 0.20 0.10 0.10 0.58 0.20 0.10 0.10 0.53 0.22 0.12 0.10
7 AMD 0.22 0.10 0.02 0.08 0.31 0.15 0.06 0.09 0.34 0.16 0.07 0.09 0.29 0.14 0.05 0.09 0.32 0.16 0.04 0.11
8 AMD 0.31 0.10 0.04 0.07 0.32 0.13 0.06 0.07 0.39 0.17 0.06 0.11 0.39 0.14 0.06 0.09 0.34 0.14 0.04 0.10
9 AMD 0.16 0.05 0.02 0.03 0.24 0.07 0.03 0.04 0.19 0.06 0.03 0.03 0.18 0.07 0.03 0.04 0.22 0.09 0.03 0.06
10 AMD 0.27 0.07 0.02 0.05 0.23 0.07 0.03 0.04 0.30 0.09 0.03 0.06 0.33 0.14 0.04 0.10 0.27 0.14 0.03 0.11
Values represent mean in μmol/L; N = 10; S = Subject; V1 = visit 1, V2 = visit 2, V3 = visit 3, V4 = visit 4, V5 = visit 5; TL = total lutein, 
TZ = total zeaxanthin, MZ = meso-zeaxanthin, Z = zeaxanthin; Group: 1: Normal; 2: AMD.
TABLE 6 Average macular pigment optical density at each degree of eccentricity for all subjects
MPOD V1 V2 V3 V4 V5 p-Value
0.25 0.39 ± 0.19 0.49 ± 0.18 0.52 ± 0.22 0.57 ± 0.26 0.61 ± 0.26 p < 0.017
0.5 0.38 ± 0.16 0.43 ± 0.15 0.46 ± 0.16 0.44 ± 0.18 0.45 ± 0.18 p < 0.101
1.0 0.26 ± 0.15 0.29 ± 0.14 0.32 ± 0.10 0.32 ± 0.17 0.38 ± 0.14 p > 0.030
1.75 0.14 ± 0.10 0.17 ± 0.10 0.17 ± 0.06 0.16 ± 0.08 0.16 ± 0.09 p > 0.610
Total average 0.29 ± 0.13 0.34 ± 0.12 0.37 ± 0.12 0.37 ± 0.15 0.40 ± 0.15 p < 0.019
Values represent mean ± SD; N = 9 (as one subject, 10, was unable to use the Densitometer and was, therefore, unable to have her 
MPOD measured); MPOD = macular pigment optical density; V1 = visit 1, V2 = visit 2, V3 = visit 3, V4 = visit 4, V5 = visit 5; 0.25 = 0.25° 
retinal eccentricity; 0.5 = 0.5° retinal eccentricity; 1.0 = 1° retinal eccentricity; 1.75 = 1.75° retinal eccentricity; Total average = average 
MPOD for all eccentricities. The p-values represent repeated measures ANOVA for the 5 study visits, with Huynh-Feldt corrections 
for lack of sphericity.
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correlation was seen for TZ (MZ + Z combined), which 
was statistically significant (r = -0.805, p = 0.009).
Interestingly, however, and for MZ only, the cor-
relation is much closer to zero when we compare 
V5-V1 change rather than V2-V1 change (i.e., V5-V1 
serum concentrations of MZ vs V5-V1 MPOD at 0.25°: 
r = -0.028, p = 0.943, Figure 8B); whereas, for TL and TZ 
the change in serum concentrations of these carote-
noids versus the change in MPOD at 0.25° remained 
inverse at visit 5 (r = -0.434 and -0.671, respectively).
Typical versus Atypical MPOD Spatial Profile
Recent studies have been concerned with the spatial 
profile and distribution of MPOD. 30,35–38 Of note, in 
the present study, four subjects (one Normal sub-
ject [Group 1]—Subject 5; and three AMD subjects 
[Group 2]—Subjects 6, 7, and 9) who displayed an 
atypical MPOD spatial profile at baseline (i.e., pre-
 supplementation), had the more typical MPOD spa-
tial profile (i.e., highest MPOD at the center) after 
eight weeks of supplementation with MZ, L, and Z 
(i.e., the formulation used in this study). The MPOD 
spatial profile, averaged for the above four subjects, 
at pre(baseline) and post-supplementation (after 8 
weeks) is presented in Figure 9 and their individual 
spatial profiles, at these two time points, are presented 
in Figure 10.
DISCUSSION
The MOST study was designed to investigate macu-
lar and serum responses to supplementation with the 
three macular carotenoids (in which MZ predominates: 
7.3 mg of MZ, 3.7 mg of L, and 0.8 mg of Z), in normal 
healthy subjects and patients with early AMD. MPOD 
was measured using cHFP at 0.25°, 0.5°, 1°, and 1.75° 
retinal eccentricity with a reference point at 7°, every 
two weeks over a 60 day (two months) study period. 
A blood sample was also collected at each study visit 
in order to analyze serum concentrations of MZ, TL, 
TZ, and Z.
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FIGURE 7 Values presented = mean; N = 9 subjects (as 
one subject, 10, was unable to use the densitometer and 
was therefore unable to have her MPOD measured); 
MPOD = macular pigment optical density; MPOD 
0.25 = MPOD measured at 0.25° retinal eccentricity; 
MPOD 0.5 = MPOD measured at 0.5° retinal eccentricity; 
MPOD 1.0 = MPOD measured at 1.0° retinal eccentricity; 
MPOD 1.75 = MPOD measured at 1.75° retinal eccentric-
ity; MPOD spatial profile = average MPOD of all degrees 
of retinal eccentricity (0.25°, 0.5°, 1.0°, and 1.75° of retinal 
 eccentricity).
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FIGURE 8A MPOD = macular pigment optical density; 
MPOD v2-v1 = macular pigment optical density at visit 2 
minus macular pigment optical density at visit 1.
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FIGURE 8B N = 9 (as one subject, 10, was unable to use the 
densitometer and was, therefore, unable to have her MPOD 
measured); MPOD = macular pigment optical density; 
MPOD v5-v1 = macular pigment optical density at visit 5 
minus macular pigment optical density at visit 1. Of note, 
two subjects (3 and 7) demonstrated the same change in MZ 
(0.01 μmol/L) and MPOD (0.12), and, therefore, it appears 
that there are only eight data points on this graph.
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Supplementation studies to date have previously 
reported on serum response to supplementation 
with the macular carotenoids, with the majority of 
these studies reporting significant increases in serum 
 concentrations of L and/or Z following supplemen-
tation with these carotenoids.22,23,25,27,39–52 Consistent 
with these previous studies, we report statistically 
 significant increases in MZ and TL, after just two 
weeks of supplementation. Of note, average serum TL 
concentrations exhibited the highest average increase 
following supplementation with the study formulation, 
when compared to the other carotenoids (MZ and TZ). 
Our findings of a 1.3-fold increase in serum concentra-
tions of L are consistent with previous studies, as our 
study formulation contained only 3.7 mg. For example, 
Bone et al. supplemented two subjects with 5 mg of L 
per day for 120 days and reported a 3-fold increase 
in serum concentrations of this carotenoid.51 Similarly, 
Berendschot et al. supplemented 8 subjects with 10 mg 
of L per day for 12 weeks and reported a 5-fold increase 
in serum concentrations of this carotenoid.39
In our study, serum concentrations of Z showed no 
significant increase over the study period, and this may 
be attributable to the low amount of Z in the formula-
tion (only 0.8 mg per capsule). Previous studies have 
reported significant increases in serum concentrations 
of Z following supplementation, albeit with a higher 
concentration of this carotenoid (e.g., Schalch et al. 
(2007): 12.6 mg Z for 17 weeks showed an increase 
of ∼ 1.09 μmol/L; Bone et al. (2003): 30 mg of Z for 
one year showed an increase of 0.52 μmol/L) in the 
preparation.43,51
We report a statistically significant increase in serum 
concentrations of MZ, with a 3-fold increase observed 
over the 8-week study period (i.e., mean MZ: V1 = 0.02 
μmol/L; mean MZ V2 = 0.06 μmol/L). However, it is 
important to point out that while MZ demonstrated a 
3-fold increase in serum (from its baseline value), that 
following supplementation, when absolute average 
MZ serum concentrations are compared with average 
absolute serum L concentrations, we see that there 
is significantly more circulating L than MZ in serum 
(mean ± SD: 0.36 ± 0.12 μmol/L versus 0.06 ± 0.03 for 
L and MZ, respectively). Also, when our concentra-
tion increase is compared to the studies carried out 
by Thurnham et al. and Bone et al., it can be seen 
that our serum MZ response was much lower when 
compared to those studies (i.e., mean ± SD serum MZ 
concentration μmol/L = 0.209 ± 0.128 and 0.094 ± 0.071, 
respectively. However, it should be noted that the 
supplement used in the study by Thurnham et al. was 
suspended in oil; whereas, our study used a micro-
encapsulated form of the supplement suspended in 
starch, which may account for, at least in part, the low 
serum response reported here, given that oil has been 
shown to promote carotenoid absorption.53
The investigation by Thurnham et al. (2008) reported 
an average increase of 0.209 ± 0.128 μmol/L in serum 
concentrations of MZ (following supplementation with 
8 mg per day of this carotenoid over a 22-day study 
period).27 Similarly, the study by Bone et al. observed 
augmented average serum concentrations of MZ 
(0.094 ± 0.071 μmol/L) following supplementation 
with 14 mg per day of this carotenoid over a 120-day 
period.25
The study, conducted by Thurnham et al. (2008), 
reported on the absorption of MZ following supple-
mentation with this carotenoid. Also, they compared 
the plasma responses to supplementation with a formu-
lation containing MZ (Lutein Plus®) with formulations 
containing L and Z (but not MZ), and reported that 
the increases seen in plasma L and Z concentrations 
were similar for each formulation, suggesting that MZ 
has little effect on absorption of L and/or Z. However, 
although Thurnham et al. reported that MZ did not 
decrease the absorption of L and Z, it is important to 
note that the study formulation used in that study 
contained more L than MZ (8 mg MZ, 10.8 mg L and 
1.2 mg Z); whereas, in our study, the formulation con-
tained more MZ than L (i.e., 7.3 mg MZ, 3.8 mg L and 
0.8 mg Z). Thus, it may not be possible to extrapolate 
directly the effects of MZ on the absorption of L and Z 
to our study without further work. Of note, the studies 
conducted by Thurnham et al. and Bone et al. are the 
only two studies to date that have investigated serum 
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FIGURE 9 Mean macular pigment optical density spatial 
profile for four subjects at visit 1 (pre-supplementation) who 
displayed the atypical MPOD spatial profile and for the same 
four subjects at visit 5 (after 8 weeks of  supplementation) 
having augmented their central MPOD. Mean (±  standard 
error); N = 4 (1 normal subject and 3 AMD subjects); Visit 
1 = average macular pigment optical density of four  atypical 
subjects at baseline; visit 5 = average macular  pigment 
optical density of same four subjects at week 8 (post 
 supplementation).
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carotenoid response following supplementation with 
a preparation containing MZ, making any discussion 
with respect to our finding difficult.25,27 Also, no study 
to date has investigated and/or reported on histology 
or retinal function in response to MZ supplementa-
tion.
To our knowledge, no study to date has reported the 
presence of MZ in human serum pre-supplementation 
with this carotenoid. This notion is unsurprising, given 
that MZ is not found in a typical western diet (with the 
exception of some unusual foods and shellfish).20 How-
ever, in this current study, we detected the possible 
presence of MZ, albeit in minute concentrations, in all 
10 subjects (mean ± SD MZ in μmol/L: 0.023 ± 0.007). 
The possibility that MZ was in serum at baseline is a 
novel and interesting finding and may be explained as 
follows: MZ may be present in carotenoid-containing 
foods but as chiral chromatography is needed to sepa-
rate MZ from Z, MZ may not have been detected since 
it is rarely used. Alternatively, MZ may be generated 
in serum following L transformation. However, the 
paucity of studies investigating any aspect of MZ in 
the diet and/or serum renders any discussion with 
respect to our finding that MZ is present in the serum 
of unsupplemented subjects difficult, and further study 
is warranted to fully investigate this assumption.
This current study is the first investigation into the 
spatial profile of MPOD (i.e., at 0.25°, 0.5°, 1°, 1.75°) 
following supplementation with all three macular 
carotenoids (MZ, L, and Z), which enabled us to 
measure change, if any, at the above degrees of reti-
nal eccentricity, including the more central locations 
where MZ is located.18 We report increases in MPOD 
at 0.25°, 0.5°, 1°, and average MPOD across the retina 
(i.e., average of 0.25°, 0.5°, 1°, and 1.75°) during the 
study period, which became significant after just two 
weeks of supplementation. The rapid increase seen 
in MPOD in the current study is a somewhat novel 
finding as, to our knowledge, previous studies have 
not measured and/or reported on MPOD after two 
weeks of supplementation. In other words, previous 
studies to date have only reported on change in MP 
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FIGURE 10 Individual macular pigment optical density spatial profiles for subjects 5, 6, 7 and 9 at visit 1 (pre-supplementation) 
who displayed the atypical MPOD spatial profile and for the same four subjects at visit 5 (after 8 weeks of supplementation) 
having augmented their central MPOD. Data presented here = mean (± standard deviation); subject 5 = normal group subject; 
subjects 6, 7, and 9 = AMD group subjects.
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levels, if any, after four weeks of supplementation and 
beyond.
Our findings are consistent with a study conducted 
by Hammond et al. (1997), who reported significant 
MPOD augmentation following dietary modification 
(i.e., corn 0.4 mg L and 0.3 mg Z and spinach 10.8 mg 
L and 0.3 mg Z) after just four weeks of dietary inter-
vention.22 Our observation is also consistent with pre-
vious reports that have investigated MP response to 
macular carotenoid supplementation (Table 1). In con-
trast, however, we found no significant augmentation 
of MPOD at 1.75° eccentricity. Also, and of interest, 
we observed the greatest increase in MPOD at 0.25°, 
with a mean ± SD increase of 0.16 ± 0.05 ODU at this 
eccentricity. Of note, no study to date has measured 
MPOD at this eccentricity following supplementa-
tion with MZ, L, and Z, and, therefore, it is difficult 
to make direct comparisons with other reports. It 
is likely that the significant increase seen in central 
MPOD in this study may be due to either MZ and/or 
L, especially given that MZ and L demonstrated sig-
nificant responses in serum concentrations; however, 
with respect to MZ, this novel finding is interesting 
given that MZ is the dominant carotenoid in the study 
formulation (i.e., 7.3 mg [62%]) and given that the ratio 
of MZ to L, and the ratio of MZ to Z, is greater at the 
center of the fovea. For example, in 1997, Bone et al. 
reported that the proportions of MZ:Z in the central 
3 mm of the macula was 0.83 which decreased with 
increasing distance from the fovea.18 Also, it is impor-
tant to note that although the mean concentration of 
MZ was only 0.06 umol/L at visit 2, this represents 
∼160 × 103 ng of MZ per 5 liters of blood. This obser-
vation is important, given that the amount of MZ in 
human donor eyes has been reported as ∼7.7 ng and 
also given that an active binding protein for Z and 
MZ have been identified in retinal tissue.53–55 There has 
only been one other study to date that has measured 
MPOD following daily supplementation with MZ. 
That study, recently performed by Bone et al., in 2007, 
included 10 normal subjects, who were supplemented 
with 14.9 mg of MZ, 5.5 mg of L, and 1.4 mg of Z, for 
120 days. Bone and co-workers reported a significant 
increase in MPOD at 0.75° of retinal eccentricity (mean 
increase = 0.07 ODU at this eccentricity) over the study 
period; however, in their study, MP was measured at 
only one retinal location (0.75°).25
As mentioned above, previous studies reporting on 
MPOD response to supplemental L and Z have reported 
parallel increases between these variables. In 1997, 
Hammond et al. showed MPOD augmentation follow-
ing dietary modification after four weeks.  Interestingly, 
two of the 11 subjects in that study did not respond 
at the macula, despite a significant increase found in 
serum concentrations of L and Z. Hammond et al. 
referred to these subjects as “retinal non-responders.”22 
Our findings are consistent with this, we found that one 
of the 10 subjects recruited (Subject 4) into our trial did 
not respond at the macula, despite significant increases 
found in serum concentrations of MZ and L. In fact, 
and of particular interest, this subject displayed one 
of the highest increases in serum macular carotenoid 
concentrations. Also, this subject displayed a “typical” 
MPOD spatial profile and had the highest MPOD level 
(of subjects in this study), at baseline (i.e., 0.72 ODU at 
0.25° retinal eccentricity). It is possible that this subject′s 
macula was saturated with MP, thus precluding the 
possibility of MP augmentation in response to supple-
mentation. However, a longer supplementation period 
and follow-up may have resulted in MPOD augmenta-
tion for this subject.
Unexpectedly, we report an inverse trend between 
rises in serum concentrations of MZ, TL, and TZ 
(V2-V1) and increases in MPOD at 0.25°, 0.5°, 1° eccen-
tricity and in average MPOD across the retina (V2-V1). 
Interestingly, however, this trend disappeared when 
we investigated the relationship between change in 
MPOD (at 0.25°) from V5 and V1 and change in serum 
MZ from V5 and V1, whereas, it remained inverse for 
the relationship between change in MPOD (at 0.25°) 
from V5 and V1 and change in serum TL and TZ from 
V5 and V1. This somewhat unexpected and appar-
ently contradictory finding may simply be explained 
by the fact that circulating MZ was captured by tis-
sues more rapidly in subjects with depleted levels 
of this carotenoid at the macula and/or other target 
tissues (e.g., fat cells). This hypothesis is supported by 
our finding that the observed inverse trend between 
change in MPOD and change in serum MZ did not 
persist beyond V3. The above findings must, how-
ever, be interpreted with appreciation of the small 
sample size of our study and further study into this 
relationship is merited.
Another interesting finding from our study was the 
observation that four subjects (one normal and three 
AMD) exhibited an atypical MPOD spatial profile at 
baseline (i.e., secondary peak). Interestingly, however, 
following supplementation with MZ, all subjects exhib-
ited the more typical MPOD spatial profile (exponential 
like decline),7,12 after just eight weeks of supplementa-
tion. In other words, it is tempting to hypothesise that 
the subjects who displayed the atypical MPOD spatial 
profile at baseline were exhibiting a relative lack of 
MP centrally (and, therefore, MZ), perhaps due to an 
inability to convert L to MZ at this location, but were 
able to rebuild their central MP peak with a supple-
ment containing MZ.
While our findings are interesting, it is important to 
note the limitations inherent in our study design, and 
these include: the sample size of this trial was small 
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(n = 10), it was a non-blind open-labeled study, and 
the period of follow-up was only 8 weeks (60 days). 
Currently we are awaiting the results of a double 
blind, randomized, placebo controlled trial (MOST 2 
[ISRCTN60816411]) investigating serum and macular 
response, in a normal healthy population, to a supple-
ment containing the three macular carotenoids (10.6 mg 
of MZ, 5.9 mg of L, and 1.2 mg of Z). Also, a second 
pilot study, in AMD patients over a longer period of 
time will compare a formulation of L and Z only, with 
a formulation of all three macular carotenoids (MZ, L, 
and Z), and a follow-up on double blind randomized 
trial comparing these formulations is also envisaged. 
This study will further enhance our understanding of 
serum and macular response to supplements contain-
ing the macular carotenoids in both normal and AMD 
subjects.
In conclusion, we report significant increases in 
serum concentrations of the macular carotenoids 
following supplementation with a formulation con-
taining 7.3 mg MZ, 3.7 mg L, and 0.8 mg Z and also 
a significant increase in MPOD (and alteration of its 
spatial profile). Also, this pilot study has identified 
the presence of MZ in human serum pre-supplemen-
tation, and the ability of this carotenoid formulation to 
rebuild central MPOD in subjects who display atypical 
profiles at baseline.
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